Glycolytic inhibitor 2-Deoxy-D-glucose attenuates SARS-CoV-2 multiplication in host cells and weakens the infective potential of progeny virions.

Related Posts

• SARS-CoV-2 Variant Delta Potently Suppresses Innate Immune Response and Evades Interferon-Activated Antiviral Responses in Human Colon Epithelial Cells
• Study demonstrates Delta variant of coronavirus could evade our immune system better.
• Coronavirus particles found in air can infect humans, experiments show
• New device to wipe out COVID threat from enclosed spaces
• First indigenous COVID drug to be made available soon
• Delta variant learned to last for longer duration in the host, CCMB study
• Indian scientists develop self-disinfecting, biodegradable face masks to combat COVID-19
• How is genome sequencing of Covid samples done at CCMB’s NGS labs?
• Omicron is driving 3rd wave, but don’t use other countries’ data for Indian trends: CCMB chief
• CCMB invites startups to join fight against COVID